Incyte strengthens its presence in SwitzerlandMonday, 5 March 2018
American biopharmaceutical company Incyte will bring together its Swiss clinical development and marketing activities at a single site in Morges.
From the second half of 2019, the city of Morges will be home to the European headquarters of American biopharma group Incyte. The company will be based in a brownfield area in the immediate vicinity of a well-connected train station in the heart of the Lake Geneva region. 150 people will work there.
“Since 2014, our European team has increased tenfold and we are delighted to bring together our Swiss-based staff in Morges. This will create new opportunities for synergies and integration," explained Nicolas Ristic, Regional Vice-President, Head of European Human Resources & Facilities, in a statement. "The Morges site will provide us with the space we need to allow our current and future teams to grow. It will also support the clinical development of our important pipeline of products."
Founded in 2002 in Wilmington, Delaware, Incyte focuses on the discovery, development and commercialization of novel medicines for cancer and other serious diseases. In November last year, the company announced its plans to further expand its operations in Switzerland via the establishment of a 60,000 m2 production plant at the Y-PARC Science and Technology Park in Yverdon-les-Bains.